DevelRx Logo

Professor David Heal, Dr Sharon Smith and Dr Reem Elbekai will be co-presenting two posters on Centanafadine at the American College of Toxicology (ACT) Virtual Meeting (November 12th to 19th 2020).

Back to News & Events

Professor David Heal, Dr Sharon Smith and Dr Reem Elbekai will be co-presenting two posters on Centanafadine at the American College of Toxicology (ACT) Virtual Meeting (November 12th to 19th 2020).

Centafadine is Otsuka’s drug-candidate that is in late-stage development for the treatment of ADHD and the posters report experimental results from the non-clinical assessment of Centanafadine’s risk for human abuse.

The poster session is scheduled for Monday 16th November at 17.00 – 18.30h (EST) [22.00-23.30h (UK time)].

P: 507

An investigation of the reinforcing potential of centanafadine in rats trained to self-administer cocaine.

David Heal, Sharon Smith, Harriet Day, Zara Turnbull, Reem Elbekai

P: 518

An investigation of the discriminative properties of centanafadine in rats trained to discriminate d-amphetamine from saline.

Reem Elbekai, Helen Rowley, David Heal

DevelRx Logo

Biocity,

Pennyfoot Street,

Nottingham,

Nottinghamshire,

NG1 1GF

inform@develrx.com

Follow us on LinkedIn

Registered in England and Wales

Company number: 12028847

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. However you can read our Cookie Policy for more information.